MetaCap

Jade Biosciences Inc. (JBIO)

NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.31+0.25 (+1.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

JBIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.83
Ex-dividend date
Apr 29, 2025
52-week range
11.32 – 28.00
Day range
15.00 – 15.53
Volume / Avg
1.02M / 917.21K
Beta
—

52-week range

$11.32$28.00

JBIO stock today

On Nov 20, JBIO ended the session at $15.31, adding $0.25 (1.66%), versus the S&P 500's 3.70% decline. At this level, JBIO sits in the middle of its 52-week range of $11.32 to $28.00: 45.3% below the high, set on Apr 27, 2026 and 35.2% above the low. JBIO is down 0.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 27.6%.

Jade Biosciences has posted a net loss over the last twelve months (EPS of -$1.83), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Jade Biosciences

Company profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Tom Frohlich
Headquarters
Waltham, MA
Employees
55
IPO year
2021

Financial highlights

Full financials

Jade Biosciences reported a net loss of $127.4 million, compared with a loss of $69.6 million a year earlier. Diluted earnings per share came in at -$3.19.

Jade Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-127.41M$-69.63M$-75.52M$-51.51M$-22.96M
EPS (diluted)$-3.19$-2.44$-2.87$-2.10$-1.87

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$49.38+222.53%

  • Strong buy 0
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $77.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.42 vs $-0.73
Surprise
+42.47%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$2.40
Ex-dividend date
Apr 29, 2025

JBIO news

All JBIO news

Jade Biosciences peers

Health Care sector
JBIO peer companies
CompanyPrice% ChgMarket capCompare
NKTRNektar Therapeutics30.20-7.19%$1.03Bvs JBIO
CTYCity Therapeutics Inc.19.32+5.29%$1.03Bvs JBIO
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs JBIO
KARDKardigan Inc.11.54-7.83%$1.08Bvs JBIO
OMEROmeros Corporation13.21-5.71%$983.66Mvs JBIO
AAPGAscentage Pharma Group International American Depository Shares11.97-3.78%$1.12Bvs JBIO
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs JBIO
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs JBIO

Indexes, lists and sector

Jade Biosciences stock FAQ

What is Jade Biosciences's stock price today?

JBIO last traded at $15.31 as of Nov 20, 4:00 PM EST, up 1.66% on the day. Prices are delayed at least 15 minutes.

Does Jade Biosciences pay a dividend?

Yes. Jade Biosciences pays $0.00 per share annually. The most recent dividend of $2.40 had an ex-dividend date of Apr 29, 2025.

Who is Jade Biosciences's CEO?

Mr. Tom Frohlich is the chief executive officer of Jade Biosciences Inc., which has about 55 employees.

Has JBIO ever split its stock?

Yes. The most recent JBIO stock split was a 1-for-35 split on Apr 29, 2025.

What is the JBIO 52-week high?

The 52-week high for JBIO is $28.00 and the 52-week low is $11.32. The stock is currently 45.3% below its high.

Compare JBIO